Webinar: The clinical value of cystatin C, by Dr. E. Sundrehagen, CSO

08. Sep 2020 | 3 min read

Webinar: The clinical value of cystatin C, by Dr. E. Sundrehagen, CSO

Cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function, as a reduction in the GFR causes a rise in the concentration of cystatin C. In this webinar Dr. Erling Sundrehagen, the co-founder of Gentian and the company’s CSO, will elaborate on the following topics:

  • Determining Glomerular Filtration Rate (GFR)
  • The history of cystatin C
  • Properties of cystatin C and its clinical value
  • Interference and avian antibodies
  • The benefits of the Gentian Cystatin C immunoassay
  • Cystatin C in addition to creatinine

Watch the webinar here

 

 

 

The Gentian Cystatin C Immunoassay

The Gentian Cystatin C Immunoassay was Gentian’s first product and was launched in 2006, filling the significant gap in the IVD market for a high quality, sensitive, turbidimetric cystatin C immunoassay.

  • ERM-DA471/IFCC standardised
  • FDA510 (k) cleared and CE-marked
  • Available for a wide range of clinical analysers with documented high inter instrument accuracy1
  • One of the methods used to evaluate the commutability of the World standard produced by IFCC2
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)

Contact us

Please send an email to marketing@gentian.com or fill out the form below to get in touch with Product Manager for cystatin C

References

  1. Eckfeldt JH et al. Arch Pathol Lab Med 2015;139:888-93
  2. Grubb A et al. Clin Chem Lab Med 2010;48: 16-19

 

 

You may also read


Canine CRP customer story - First-line test to detect inflammation

Jan 29, 2026

Canine CRP customer story - First-line test to detect inflammation

Gentian Canine CRP continuously available since 2013 The Gentian Canine CRP immunoassay, available since..

Cystatin C, GFR and Shrunken Pore Syndrome: Insights from Dr. A. Grubb

Jan 20, 2026

Cystatin C, GFR and Shrunken Pore Syndrome: Insights from Dr. A. Grubb

Expanding the understanding of kidney disease Shrunken Pore Syndrome (SPS) and Selective Glomerular..

GCAL® Calprotectin - From insights to impact - January 2026

Jan 13, 2026

GCAL® Calprotectin - From insights to impact - January 2026

Continuing the GCAL® journey: Building on 2025, moving into 2026 Over the past year, interest in circulating..